Literature DB >> 21990558

Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel.

David Fiorella1.   

Abstract

The majority of neurological complications encountered during neuroendovascular procedures are a result of thromboembolic phenomena. This has become increasingly evident as techniques have evolved to incorporate an ever-growing volume of temporary and permanently implanted adjunctive devices. By optimizing our anti-thrombotic management strategies we can potentially improve procedural safety. The appropriate selection of anti-thrombotic regimens for neurointerventional procedures poses a unique set of challenges when compared with endovascular interventions in other vascular territories. Neurological procedures frequently target lesions that have hemorrhaged or have a lethal hemorrhagic potential-thus requiring that the operator maintain a tenuous balance between bleeding and thrombosis. Neurological end-organs are unforgiving, even of small emboli, further magnifying the implications of inadequate therapy. The spectrum of disease processes encountered within the context of routine clinical practice is very heterogeneous and each lesion requires a specific anti-thrombotic strategy. The diseases treated (eg, aneurysms, AVM, acute ischemic stroke, chronic atherosclerotic stenosis) are relatively uncommon in comparison with coronary or peripheral atherosclerotic disease. The field of neurointervention itself is still relatively new and continues to evolve rapidly, with innovation frequently outpacing clinical evidence. Predictably, within this environment, there are no large, controlled trials to guide anti-thrombotic management in most cases. For these reasons, medical decision making is based largely upon an understanding of the pharmacology of the agents used and an extrapolation of the literature from other fields. In this review we discuss aspirin and clopidogrel, the two anti-platelet agents commonly used in conjunction with endovascular stents and stent-like devices. We will discuss their pharmacology and applications in neuroendovascular therapeutics with a focus on practical solutions to dilemmas that are encountered during the course of daily clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21990558     DOI: 10.1136/jnis.2009.001859

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  5 in total

1.  Acute life-threatening hemorrhage in patients with head and neck cancer presenting with carotid blowout syndrome: follow-up results after initial hemostasis with covered-stent placement.

Authors:  H Shah; J J Gemmete; N Chaudhary; A S Pandey; S A Ansari
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-24       Impact factor: 3.825

2.  The use of cangrelor in neurovascular interventions: a multicenter experience.

Authors:  Gustavo M Cortez; André Monteiro; Nader Sourour; Frédéric Clarençon; Mahmoud Elhorany; Mikayel Grigoryan; Soz Mirza; Guilherme Dabus; Italo Linfante; Pedro Aguilar-Salinas; Yasmeen Murtaza; Amin Aghaebrahim; Eric Sauvageau; Ricardo A Hanel
Journal:  Neuroradiology       Date:  2020-11-11       Impact factor: 2.804

3.  Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting.

Authors:  J T Fifi; C Brockington; J Narang; W Leesch; S L Ewing; H Bennet; A Berenstein; J Chong
Journal:  AJNR Am J Neuroradiol       Date:  2012-11-29       Impact factor: 3.825

4.  Effect of premedication method and drug resistance of antiplatelet agent on periprocedural thromboembolic events during coil embolization of an unruptured intracranial aneurysm.

Authors:  Se Hwan Park; Yong Bae Kim; Seung Kon Huh
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2012-09-28

5.  Fatal Thrombosis of a Flow Diverter due to Ibuprofen-related Antagonization of Acetylsalicylic Acid.

Authors:  R Martinez-Moreno; M Aguilar; C Wendl; H Bäzner; O Ganslandt; H Henkes
Journal:  Clin Neuroradiol       Date:  2015-12-02       Impact factor: 3.649

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.